Comparison · NCT00445601-sae
Arm I: Gemcitabine vs Arm II: Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I: Gemcitabine vs Arm II: Placebo: serious adverse events. Trial comparisons, record NCT00445601-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00445601-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0424 | 0.0207 | 0.085 | wilson | |
| Risk in group 2 | 0.0287 | 0.0123 | 0.0655 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0137 | -0.029 | 0.0593 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.48 | 0.478 | 4.56 | log | |
| Odds ratio, group 1 over group 2 | 1.5 | 0.466 | 4.81 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm I: Gemcitabine than on Arm II: Placebo | 73.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I: Gemcitabine | Patients receive intravesical gemcitabine hydrochloride over 1 hour post-TURBT. | 7 | 165 | EG000 |
| Group 2 | Arm II: Placebo | Patients receive intravesical placebo over 1 hour post-TURBT. | 5 | 174 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Assessed every 3 months for 2 years, then every 6 months for 2 years
Source ClinicalTrials.gov
Trial
- Title
- S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
- NCT number
- NCT00445601
- Phases
- PHASE3
- Conditions
- Bladder Cancer
- Interventions
- gemcitabine hydrochloride, placebo
- Lead sponsor
- SWOG Cancer Research Network
- Results first posted
- 2018-04-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00445601?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00445601-sae